Endonovo Therapeutics

(OTC) ENDV

Current Price$0.00

Market Cap$1,800

Since IPO (2013)-100%

5 Year-100%

1 Year-100%

1 Month+0%

Endonovo Therapeutics Financials at a Glance

Market Cap

$1,800

Revenue (TTM)

$0.00

Net Income (TTM)

$2.46M

EPS (TTM)

$-0.01

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-9.75 (Low)

Dividend

$0.00

Beta (Volatility)

-9.75 (Low)

Price

$0.00

Volume

300,000

Open

$0.00

Price

$0.00

Volume

300,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Dividend

$0.00

Beta (Volatility)

-9.75 (Low)

Price

$0.00

Volume

300,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

ENDV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Endonovo Therapeutics

Industry

Biotechnology

Sector

Health Care

CEO

Alan Brian Collier

Website

www.endonovo.com

Headquarters

Woodland Hills, CA 91367, US

ENDV Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

Return on Assets

-98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.80K

Shares Outstanding

1.81B

Volume

300.00K

Avg. Volume

1.05M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$945.77K

EBITDA

$945.77K

Operating Cash Flow

$42.99K

Capital Expenditure

$0.00

Free Cash Flow

$42.99K

Cash & ST Invst.

$12.00

Total Debt

$6.91M

Endonovo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$1.80K

N/A

Market Cap/Employee

$1.80K

N/A

Employees

N/A

Net Income

$557.90K

+22.7%

EBITDA

$248.56K

+0.7%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Net Cash

$6.90M

+1.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$6.90M

-1.7%

Return on Assets

-98.09%

N/A

Return on Invested Capital

3.03%

N/A

Free Cash Flow

$102.76K

-80.5%

Operating Cash Flow

$102.76K

-80.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GNLKQGeneLink, Inc.

GNLKQGeneLink, Inc.$0.00+0.00%

VFRMVeritas Farms, Inc.

VFRMVeritas Farms, Inc.$0.00+0.00%

CNBXCNBX Pharmaceuticals Inc.

CNBXCNBX Pharmaceuticals Inc.$0.00+25.00%

ITMCItoco Inc.

ITMCItoco Inc.$0.00+0.00%

AMBSAmarantus BioScience Holdings, Inc.

AMBSAmarantus BioScience Holdings, Inc.$0.00+0.00%

AFFYAffymax, Inc.

AFFYAffymax, Inc.$0.00+10.00%

WIBFFWest Island Brands Inc.

WIBFFWest Island Brands Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

NIONio

NIONio$5.91-0.08%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

Questions About ENDV

What is the current price of Endonovo Therapeutics?

Endonovo Therapeutics is trading at N/A per share.

What is the 52-week range for Endonovo Therapeutics?

Over the past 52 weeks, Endonovo Therapeutics has traded between N/A and $0.00.

How much debt does Endonovo Therapeutics have?

As of the most recent reporting period, Endonovo Therapeutics reported total debt of $6.87M.

How much cash does Endonovo Therapeutics have on hand?

Endonovo Therapeutics reported $18 in cash and cash equivalents in its most recent financial results.

What is Endonovo Therapeutics’s dividend yield?

Endonovo Therapeutics does not currently have a dividend yield.

Endonovo Therapeutics

Endonovo Therapeutics Financials at a Glance

ENDV News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Endonovo Therapeutics

ENDV Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Endonovo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ENDV

What is the current price of Endonovo Therapeutics?

What is the 52-week range for Endonovo Therapeutics?

How much debt does Endonovo Therapeutics have?

How much cash does Endonovo Therapeutics have on hand?

What is Endonovo Therapeutics’s dividend yield?

Premium Investing Services